Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us

COVID-19 updates

Picture

COVID-19 Update #125 3/24/2022

3/24/2022

 
COVID-19 Anti-inflammatories
 
Synairgen announced that NIAID had discontinued the Phase II/III ACTIV-2 COVID-19 trial (NCT04518410) in March 2022, due to changes in the pandemic that necessitate a change in how COVID-19 therapies are evaluated. ACTIV-2 was evaluating several drugs in the treatment of COVID-19.
 
Eiger BioPharmaceuticals announced that in the 28-day, 4,669 patient, Phase III TOGETHER trial (NCT04727424), 2.7% of patients treated with peginterferon lambda were hospitalized or had an ER visit compared to 5.6% with placebo in non-hospitalized adult Brazilian patients with COVID-19, who were at high risk of progressing to severe illness.
 
COVID-19 Vaccines
 
The Vaccines and Related Biological Products Advisory Committee (VRBPAC), CDC and NIH will meet on 4/6/2022 to discuss additional COVID-19 vaccine boosters and how to select specific SARS-CoV-2 virus strains for COVID-19 vaccines to address current and emerging variants.
  • Pfizer and BioNTech have requested approval of a fourth dose of their COVID-19 vaccine for adults 65 and older, due to diminished protection over time against the omicron variant.
    • Pfizer and BioNTech are evaluating an Omicron specific COVID-19 vaccine in a 1,420 patient trial as a second booster (fourth dose), first booster (third dose) or as the primary vaccine in unvaccinated patients.
  • Moderna requested approval of a fourth dose of their COVID-19 vaccine for adults 18 and older, due to recent data following the emergence of the omicron variant.
    • Moderna is evaluating an Omicron specific COVID-19 vaccine in a Phase II trial in the U.S. and a Phase III trial in England.
  • An Israeli study involving 1,050 healthcare workers, who had received a Pfizer/BioNTech or Moderna COVID-19 booster dose at least four months earlier, found an increase in the immune response with a fourth dose against the omicron variant. However, vaccine efficacy was only 30% for any severity of COVID-19 with most cases being mild.
  • An analysis of data from 1,138,681 Israeli patients, who were 60 and older, found a lower rate of infection after a fourth dose of the Pfizer/BioNTech COVID-19 vaccine.
  • A CDC analysis found that mRNA COVID-19 vaccine effectiveness for the Omicron variant, two months after a booster dose, was 87% to prevent emergency room/urgent care visits (ED/UC) and 91% to prevent hospitalizations. Four months after the booster dose vaccine, effectiveness was 66% to prevent ED/UC and 91% to prevent hospitalizations. A separate study found that mRNA vaccines are 94% effective, after three doses, to prevent invasive mechanical ventilation from severe COVID-19 caused by the Omicron variant.
  • An academic analysis of mRNA COVID-19 vaccine effectiveness to prevent hospitalizations, for several SARS-CoV-2 variants, found vaccine effectiveness to be 65% after two immunizations and 85% after three for Omicron. Severity was lower when comparing Delta to Omicron infections. Patients who were vaccinated also had less severe disease for all variants.​
Moderna announced interim results from the 11,700 patient, Phase II/III KidCOVE trial (NCT04796896), where vaccine effectiveness for two 25 mcg doses of their COVID-19 vaccine demonstrate immunogenicity similar to young adults (18 to 25 years) in children 6 months to less than 6 years old. Vaccine effectiveness to prevent infections from Omicron was 43.7% in children 6 months to 2 years and 37.5% in children 2 to under 6 years. Most cases of COVID-19 were mild, and no severe disease developed in either age group.
 
Based on previously announced data in older children from the 11,700 patient, Phase II/III KidCOVE trial(NCT04796896), Moderna is requesting approval for use of its COVID-19 vaccine in children 6 to 17 years old. 


Comments are closed.
    Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker

    Archives

    January 2023
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020

    Categories

    All

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.